All-oral fixed-dose combination therapy with daclatasvir/asunaprevir/BMS-791325, ± ribavirin, for patients with chronic HCV genotype 1 infection and compensated cirrhosis: UNITY-2 Phase 3 SVR12 results

被引：8

作者：

Muir, Andrew ^{[1
]}

Poordad, Fred ^{[2
]}

Lalezari, Jacob P. ^{[3
]}

Everson, Gregory T. ^{[4
]}

Dore, Gregory J. ^{[5
]}

Kwo, Paul ^{[6
]}

Hezode, Christophe ^{[7
]}

Pockros, Paul J. ^{[8
]}

Tran, Albert ^{[9
]}

Ramji, Alnoor ^{[10
]}

Yang, Rong ^{[11
]}

Hughes, Eric A. ^{[11
]}

Swenson, Eugene S. ^{[12
]}

Yin, Philip D. ^{[12
]}

机构：

[1] Duke Univ, Sch Med, Duke Clin Res Inst, Durham, NC USA

[2] Univ Texas Hlth Sci Ctr San Antonio, Texas Liver Inst, San Antonio, TX 78229 USA

[3] Quest Clin Res, San Francisco, CA USA

[4] Univ Colorado, Sch Med, Denver, CO USA

[5] UNSW Australia, Kirby Inst, Sydney, NSW, Australia

[6] Indiana Univ Sch Med, Indianapolis, IN 46202 USA

[7] Univ Paris Est, Hop Henri Mondor, Creteil, France

[8] Scripps Clin, La Jolla, CA 92037 USA

[9] Ctr Hosp Univ Nice, Nice, France

[10] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada

[11] Bristol Myers Squibb Co, Princeton, NJ USA

[12] Bristol Myers Squibb Co, Wallingford, CT 06492 USA

来源：

关键词：

D O I：

10.1002/hep.27589

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

LB-2

引用

页码：1267A / 1268A

页数：2